ReviewCurrent heart failure reports2025
When the Heart, Kidneys, and Body Waste Away: A Review of Cachexia in Cardiorenal Syndrome.
Review in Current heart failure reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Metabolic disorder-MASLD-cardiovascular disease-kidney disease (MMCK) syndrome: an expansion of the Cardiovascular-Kidney-Metabolic (CKM) framework.Cardiovascular diabetology. Endocrinology reports · 2026Review
- Relationship between nutrition status and muscle mass and its impact on 1-year mortality in patients with aortic stenosis undergoing transcatheter aortic valve implantation.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Geriatric nutritional risk Index predicts adverse outcomes across cardiovascular-kidney-metabolic syndrome: discovery in NHANES and external validation in CKM stage 4 patients undergoing PCI.Frontiers in cardiovascular medicine · 2026Article
- Association between serum total cholesterol levels and the risk of incident heart failure in patients with atherosclerotic cardiovascular disease.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewCardiorenal syndrome refers to disorders of the heart and kidneys in which dysfunction in one organ has resulted in dysfunction of the other. Wasting continuum disorders such as cachexia are highly prevalent in cardiorenal syndrome, yet the clinical impact, pathophysiological mechanisms, and management options have not been well elucidated in previous literature. In this review, we aim to summarize current knowledge regarding the epidemiology, clinical impact, and pathophysiology of CRS-induced wasting continuum disorders, as well as highlight effective and potentially emerging treatment options. RECENT
findingsNeurohormonal activation, inflammation, metabolic dysfunction, gastrointestinal abnormalities, protein degradation, and mitochondrial pathway dysfunction are pathophysiologic mechanisms underlying CRS-induced cachexia. Recent studies have investigated various treatment options targeting such mechanisms with mixed results. Early screening of wasting continuum disorders in CRS, in combination with nutritional supplementation and exercise rehabilitation strategies, is the mainstay of management. Pharmacologic optimization may also benefit patients. Future studies are necessary to improve generalizability and consensus definitions of cardio- and renal-specific wasting continuum disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.